<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197194</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0061</org_study_id>
    <nct_id>NCT03197194</nct_id>
  </id_info>
  <brief_title>A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion</brief_title>
  <acronym>THEIA</acronym>
  <official_title>A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the THEIA study is to determine if Alteplase administrated within 4.5 hours
      improve visual deficit due to acute CRAO with a good safety profile.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity (VA) improvement after treatment</measure>
    <time_frame>1 month</time_frame>
    <description>Improvement of the VA is defined by a gain of 15 letters or more on the ETDRS VA chart or ordinal scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>3 months</time_frame>
    <description>Number, type and grade of severity of adverse drug reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of blindness patients after treatment</measure>
    <time_frame>1 month</time_frame>
    <description>Blindness is defined according to WHO revised categories of visual impairment, as VA &lt; 1/20 (&lt; 20/400 or &gt; 1.3 log.MAR) or visual field &lt; 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>3 months</time_frame>
    <description>Visual field at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of VA on ETDRS chart or ordinal scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-treatment administration impact on VA evolution.</measure>
    <time_frame>1 month</time_frame>
    <description>Mean VA improvement according to the time between onset of sign and treatment administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global disability (modified Rankin scale) after treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life related to vision (NEI-VFQ-25) after treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Central Retinal Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>A : Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of Alteplase and one tablet of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : Acetylsalicylic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one tablet of Acetylsalicylic Acid and one dose of IV placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.</description>
    <arm_group_label>A : Alteplase</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>one tablet of aspirin 300 mg</description>
    <arm_group_label>B : Acetylsalicylic Acid</arm_group_label>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid</description>
    <arm_group_label>A : Alteplase</arm_group_label>
    <other_name>Placebo aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo IV</intervention_name>
    <description>IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour</description>
    <arm_group_label>B : Acetylsalicylic Acid</arm_group_label>
    <other_name>Placebo Actilyse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 18 years to 80 years

          -  CRAO diagnosis by fundoscopic examination or non-mydriatic retinophotography (NMR)
             performed by an ophthalmologist.

          -  Blindness defined according to WHO classification as visual acuity &lt;1/20 (20/400).

          -  Treatment intervention should be initiated by a stroke team as quickly as possible and
             within 4.5 hours from symptom onset.

          -  No clinical (e.g headache with jaw claudication or scalp tenderness, no temporal
             pulse) or laboratory evidence (elevated CRP) of giant cell arteritis

          -  No clinical or radiological evidence of stroke within the last 3 months.

          -  Patients covered by health care insurance (social security)

          -  Written informed consent obtained.

        Exclusion Criteria:

          -  Symptoms onset more than 4.5 h prior to infusion start or undetermined time of symptom
             onset.

          -  Minor VA deficit or VA rapidly improving before start of infusion.

          -  CRAO without foveal ischemia.

          -  Other retinal vascular disease: occlusion of branch of the CRA without significant VA
             loss, occlusion of the retinal vein, proliferative diabetic retinopathy or any other
             severe retinopathy.

          -  Clinical or laboratory evidence of temporal arteritis.

          -  Evidence of ICH or ischemic stroke on the pre-administration CT scan or MRI.

          -  Pregnant or lactating women

          -  Minors

          -  Adults under guardianship or trusteeship

          -  Any contraindication to alteplase

          -  Any contraindication to aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit GUILLON, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit GUILLON, Dr</last_name>
    <phone>+33(0) 2 40 16 51 99</phone>
    <email>benoit.guillon@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile PRETERRE, Dr</last_name>
    <email>cecile.preterre@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie GODARD-DUCCESCHI, Dr</last_name>
      <email>sogodard@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie GODARD-DUCCESCHI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Arras</name>
      <address>
        <city>Arras</city>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick LE COZ, Dr</last_name>
      <email>Patrick.LE-COZ@ch-arras.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick LE COZ, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry MOULIN, Pr</last_name>
      <email>thierry.moulin@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry MOULIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor SIBON, Pr</last_name>
      <email>igor.sibon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Igor SIBON, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH métropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien MARCEL, Dr</last_name>
      <email>sebastien.marcel@ch-metropole-savoie.fr</email>
    </contact>
    <investigator>
      <last_name>Sébastien MARCEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yannick BEJOT, Pr</last_name>
      <email>yannick.bejot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Yannick BEJOT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cédric URBANCZYK, Dr</last_name>
      <email>cedric.urbanczyk@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Cédreic URBANCZYK, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaelle GODENECHE, Dr</last_name>
      <email>gaelle.godeneche@ch-larochelle.fr</email>
    </contact>
    <investigator>
      <last_name>Gaelle GODENECHE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle MOURAND, Dr</last_name>
      <email>i-mourand@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle MOURAND, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit GUILLON, Dr</last_name>
      <email>benoit.guillon@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit GUILLON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile PRETERRE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre LEBRANCHU, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Hélène MAHAGNE, Dr</last_name>
      <email>mahagne.h@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Hélène MAHAGNR, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael OBADIA, Dr</last_name>
      <email>mobadia@for.paris</email>
    </contact>
    <investigator>
      <last_name>Michael OBADIA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Philippe NEAU, Pr</last_name>
      <email>jean-philippe.neau@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Philippe NEAU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas RONZIERE, Dr</last_name>
      <email>thomas.ronziere@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas RONZIERE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume MARC, Dr</last_name>
      <email>g.marc@ch-saintnazaire.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume MARC, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie WOLFF, Dr</last_name>
      <email>valerie.wolff@chu-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie WOLFF, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel CALVIERE, Dr</last_name>
      <email>calviere.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel CALVIERE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Séverine DEBIAIS</last_name>
      <email>s.debiais@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Séverine DEBIAIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Central retinal artery occlusion</keyword>
  <keyword>visual acuity</keyword>
  <keyword>visual field</keyword>
  <keyword>mRs</keyword>
  <keyword>NEI-VFQ-25</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Retinal Artery Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

